Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Argan Inc’s contract backlog or spotting cost-overrun warnings means sifting through hundreds of EPC disclosures. Each 10-K details percentage-of-completion accounting, while every 8-K can signal a newly awarded gas-fired or renewable project. The problem? These filings are dense and highly technical.
Stock Titan’s AI-powered summaries turn that challenge into a two-minute read. We monitor EDGAR around the clock, surface key data as soon as a document posts, and translate accounting jargon into plain language. Whether you need the latest Argan Inc quarterly earnings report 10-Q filing to gauge segment margins or want real-time alerts on Form 4 insider moves, you’ll find it here—already distilled and cross-referenced.
- Argan Inc insider trading Form 4 transactions—track executive buys and sells within minutes.
- Argan Inc quarterly earnings report 10-Q filing—see segment revenue and backlog updates.
- Argan Inc Form 4 insider transactions real-time—receive instant alerts on material moves.
- Argan Inc SEC filings explained simply—our AI distills complex EPC disclosures.
- Argan Inc earnings report filing analysis—compare contract margins quarter over quarter.
- understanding Argan Inc SEC documents with AI—skip jargon, keep the insight.
- Argan Inc executive stock transactions Form 4—evaluate alignment of management incentives.
- Argan Inc annual report 10-K simplified—find risk factors on fixed-price contracts fast.
- Argan Inc proxy statement executive compensation—review pay tied to project milestones.
- Argan Inc 8-K material events explained—know when new EPC awards hit the books.
You can also download original PDFs, compare historical 10-Qs, and export tables for modeling—without leaving this page. From backlog disclosures to cash-flow swings, our expert analysis highlights what moves the stock so you can make informed decisions sooner.
Karen A. Sweeney, a director of ARGAN INC (AGX), reported a sale of company stock on September 19, 2025. She sold 390 shares of the issuer's common stock on the open market at a price of $264.25 per share and after the transaction beneficially owned 1,315 shares directly. The Form 4 was signed by the reporting person on September 22, 2025. The filing records the transaction type as an open-market sale and specifies direct ownership following the sale.
James W. Quinn, a director of Argan Inc. (AGX), disclosed open-market sales of the issuer's common stock on September 19 and September 22, 2025. He sold 11,897 shares on September 19 at an average price of $260.73 per share, leaving 4,660 shares held directly after that transaction. He then sold the remaining 4,660 shares on September 22 at an average price of $259.35 per share, leaving no direct holdings. The filing also shows indirect ownership of 63,014 shares through the James W. Quinn 2025 GRAT No.1. The transactions are reported on a Form 4 and were signed by Mr. Quinn on September 22, 2025.
Charles E. Collins IV, CEO of Argan, Inc. (AGX), reported option exercise and subsequent open-market sale on 09/18/2025. He exercised 7,500 shares of a stock option granted 09/12/2018 at an exercise price of $43.10 per share, and immediately sold 7,500 shares on the open market at $257.39 per share. Following these transactions the filing shows 21,006 shares beneficially owned directly and 44,735 shares underlying options/derivatives reported as beneficially owned. The Form 4 is signed and dated 09/22/2025.
Form 144 Notice — ARGAN INC (AGX): This filing notifies a proposed sale of 1,000 common shares through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value of $264,535.10 and an approximate sale date of 09/19/2025. The shares were acquired on 04/17/2020 via previously exercised options and paid in cash. The filer discloses two recent sales by the same person in the past three months: 2,609 shares sold on 09/17/2025 for $625,325.12 and 3,465 shares sold on 06/26/2025 for $734,630.59. The filer attests there is no undisclosed material adverse information.
Form 144 notice for Argan, Inc. (AGX) shows a proposed sale of 16,557 shares of common stock through Allen & Company on 09/19/2025, with an aggregate market value of $4,297,866.06. The filing lists 13,811,575 shares outstanding. The shares to be sold were acquired recently: 56,167 shares on 06/09/2025 via an equity grant (paid via option exercise) and 390 shares on 06/10/2025 as a time-based restricted stock issuance. The filer reports no securities sold in the past three months and includes the standard representation that no undisclosed material adverse information is known.
ARGAN, Inc. (AGX) submitted a Form 144 notifying the SEC of a proposed sale of 390 shares of common stock through Raymond James & Associates on 09/19/2025 with an aggregate market value of $103,014.60. The filing reports 13,811,575 shares outstanding for the issuer.
The 390 shares were acquired on 06/10/2025 as a time-based restricted stock issuance from the issuer and were paid on that same date. The filer reports no securities sold in the past three months and includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
ARGAN, Inc. (AGX) Rule 144 notice: The filer plans to sell 49,401 shares of common stock through Raymond James on the NYSE with an aggregate market value of $11,955,042, based on the filing. The shares reported for sale were acquired on 09/18/2025 as an equity grant from the issuer and the payment/transfer is listed as an option exercise on the same date. The filing also discloses two sales by the same person within the prior three months: 1,500 shares sold on 07/29/2025 for $362,250 and 5,000 shares sold on 07/31/2025 for $1,225,000. The filer represents no undisclosed material adverse information.
Peter W. Getsinger, a director of Argan Inc. (AGX), exercised stock options and sold a portion of the resulting shares in mid-September 2025. On 09/15/2025 he exercised the remaining 3,000 shares under an option granted 01/07/2016 at an exercise price of $30.44 per share using net settlement, resulting in a reported beneficial ownership of 15,505 shares. On 09/17/2025 he sold 2,609 shares on the open market at $239.68 per share, after which his reported beneficial ownership in common stock was 12,896 shares. The filing shows 3,000 option shares exercised and a remaining derivative position reported as 28,500 option-related shares.
Form 144 notice for ARGAN INC (AGX) reports a proposed sale of common shares by an insider through Morgan Stanley Smith Barney. The filer plans to sell 2,609 shares with an aggregate market value of $625,325.12 on the NYSE, and reports the acquisition of those shares on 09/17/2025 by exercising options under a registered plan and paying cash on the same date. The filing also discloses prior sales by the same person: 3,465 shares sold on 06/26/2025 for $734,630.59. The notice includes the seller's representation that no undisclosed material adverse information is known.
Rainer H. Bosselmann, identified as a former CEO & Director of Argan, Inc. (AGX), filed a Form 4 reporting a disposition of 196,723 shares on 09/15/2025. The filing states this is the reporting person's final filing because he has ended service as an officer/director and is no longer subject to Section 16 reporting. The Form 4 lists Bosselmann's mailing address as Arlington, VA, and shows the filing was signed by Beverley M. Bosselmann, Attorney-in-Fact.
FAQ
What is the current stock price of Argan (AGX)?
What is the market cap of Argan (AGX)?
